EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Janux Therapeutics's enterprise value is $2,697.70 Mil.
Janux Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $8.08 Mil. Therefore, Janux Therapeutics's EV-to-Revenue for today is 333.75.
The historical rank and industry rank for Janux Therapeutics's EV-to-Revenue or its related term are showing as below:
JANX'
s EV-to-Revenue Range Over the Past 10 Years
Min: -216.37 Med: 31.84 Max: 2454.65
Current: 333.75
During the past 5 years, the highest EV-to-Revenue of Janux Therapeutics was 2454.65. The lowest was -216.37. And the median was 31.84.
JANX's EV-to-Revenue is ranked worse than 90.14% of 1034
companies
in the Biotechnology industry
Industry Median: 7.82
vs JANX: 333.75
The historical data trend for Janux Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Janux Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Janux Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Janux Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Janux Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Janux Therapeutics's EV-to-Revenue falls into.
Janux Therapeutics's current Enterprise Value is $2,697.70 Mil.
Janux Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Janux Therapeutics's share price for today is $62.43.
Janux Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.18.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Janux Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Janux Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Janux Therapeutics (Janux Therapeutics) Business Description
Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
JANX has been successfully added to your 